Background: In the context of precision medicine, understanding patient-specific variation is an important step in developing targeted and patient-tailored treatment regimens for periodontitis. While several studies have successfully demonstrated the usefulness of molecular expression profiling in conjunction with single classifier systems in discerning distinct disease groups, the majority of these studies do not provide sufficient insights into potential variations within the disease groups. Aim: The goal of this study was to discern biological response profiles of periodontitis and non-periodontitis smoking subjects using an informed panel of biomarkers across multiple scales (salivary, oral microbiome, pathogens and other markers). Material & Methods: The investigation uses a novel ensemble classification approach (SVA-SVM) to differentiate disease groups and patient-specific biological variation of systemic inflammatory mediators and IgG antibody to oral commensal and pathogenic bacteria within the groups. Results: Sensitivity of SVA-SVM is shown to be considerably higher than several traditional independent classifier systems. Patient-specific networks generated from SVA-SVM are also shown to reveal crosstalk between biomarkers in discerning the disease groups. High-confidence classifiers in these network abstractions comprised of host responses to microbial infection elucidated their critical role in discerning the disease groups. Conclusions: Host adaptive immune responses to the oral colonization/infection contribute significantly to creating the profiles specific for periodontitis patients with potential to assist in defining patient-specific risk profiles and tailored interventions.
|Number of pages||9|
|Journal||Journal of Clinical Periodontology|
|State||Published - Mar 1 2017|
Bibliographical noteFunding Information:
Conflict of interest and source of funding statement The authors have stated explicitly that there are no conflict of interests in connection with this article. This work was supported by USPHS grants P20RR020145, P20GM103538 and UL1TR000117 from the National Institutes of Health. We thank M.J. Steffen and J. Stevens for expert technical assistance in the evaluation of the biomarkers in the serum samples.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
- oral bacteria
ASJC Scopus subject areas